Pure Global

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients - Trial NCT06379360

Access comprehensive clinical trial information for NCT06379360 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital of Soochow University and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 77 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06379360
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06379360
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients: A Single Arm, Multi Center Clinical Trial

Study Focus

Acute Myeloid Leukemia

Hypomethylating agent, Azacitidine or Decitabine

Interventional

drug

Sponsor & Location

The First Affiliated Hospital of Soochow University

Suzhou, China

Timeline & Enrollment

Phase 2

Nov 01, 2020

Dec 31, 2028

77 participants

Primary Outcome

Relapse free survival (RFS)

Summary

HMA maintenance therapy is expected to benefit overall survival (OS) and relapse free
 survival (RFS) in AML patients with favorable risk.

ICD-10 Classifications

Myeloid leukaemia
Acute myeloblastic leukaemia [AML]
Myeloid leukaemia, unspecified
Acute myelomonocytic leukaemia
Acute myeloid leukaemia with 11q23-abnormality

Data Source

ClinicalTrials.gov

NCT06379360

Non-Device Trial